Triumvira Immunologics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.triumvira.com
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Phase 1
Active, not recruiting
- Conditions
- Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT05862324
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
TAC T-cells for the Treatment of HER2-positive Solid Tumors
Phase 1
Terminated
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction CancerHER2 Positive Gastric Cancer
- Interventions
- Biological: TAC01-HER2 plus pembrolizumabBiological: TAC01-HER2
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04727151
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Rutgers Cancer Institute of New Jersey, Newark, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Phase 1
Withdrawn
- Conditions
- Lymphoma, B-Cell
- Interventions
- Biological: TAC01-CD19
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Registration Number
- NCT03880279
© Copyright 2025. All Rights Reserved by MedPath